Literature DB >> 22821377

Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia.

Vikramjeet Singh1, Elke Verena Voss, Karelle Bénardais, Martin Stangel.   

Abstract

2-chlorodeoxyadenosine (CdA, Cladribine) is an immunosuppressant that has recently been shown to be effective in the treatment of multiple sclerosis (MS). There is extensive clinical experience with CdA for the treatment of neoplastic diseases, especially hematologic malignancies, due to its apoptotic effects on leukemic and several other neoplastic cells. Furthermore, CdA crosses the blood-brain-barrier and thus may also exert its effects directly on cells of the central nervous system (CNS). Therefore, we have studied the effects of CdA on cultured primary rat microglia, the resident macrophage in the CNS, which is also thought to be involved in the pathogenesis of MS. Treatment of microglia with CdA inhibited their proliferation and induced apoptosis. Phosphorylation of CdA to CdATP was required for both effects and was inhibited by deoxycytidine. Furthermore, activation of caspase-3 and -9 revealed the involvement of the intrinsic mitochondrial mediated apoptotic pathway. However, the absence of caspase-8 activation specified independency from the extrinsic death receptor mediated apoptosis. The mitochondrial membrane potential was significantly reduced after CdA exposure and was not conserved with Bax or caspase-3 inhibition. Assessment of DNA fragmentation by TUNEL and DNA-release-assay showed microglia with fragmented nuclei. Other functions of microglia like phagocytosis and LPS-induced NO and TNF-α release were not affected by CdA. These data suggest a potential of CdA treatment to induce not only leukopenia but also apoptosis in microglia in the CNS. These results help to understand the mechanism of action of CdA in CNS diseases and may open the possibility to target microglia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821377     DOI: 10.1007/s11481-012-9387-7

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  44 in total

1.  Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?

Authors:  Elke Verena Voss; Jelena Škuljec; Viktoria Gudi; Thomas Skripuletz; Refik Pul; Corinna Trebst; Martin Stangel
Journal:  Neurobiol Dis       Date:  2011-09-21       Impact factor: 5.996

2.  The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes.

Authors:  Edward T W Bampton; Christoph G Goemans; Dhevahi Niranjan; Noboru Mizushima; Aviva M Tolkovsky
Journal:  Autophagy       Date:  2005-04-21       Impact factor: 16.016

Review 3.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

Review 4.  Cladribine for multiple sclerosis: review and current status.

Authors:  Jack C Sipe
Journal:  Expert Rev Neurother       Date:  2005-11       Impact factor: 4.618

Review 5.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Acta Neurol Scand       Date:  2007-03       Impact factor: 3.209

6.  Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.

Authors:  H Bartosik-Psujek; E Belniak; K Mitosek-Szewczyk; B Dobosz; Z Stelmasiak
Journal:  Acta Neurol Scand       Date:  2004-06       Impact factor: 3.209

7.  Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.

Authors:  D A Carson; D B Wasson; R Taetle; A Yu
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

Review 8.  Microglial clearance function in health and disease.

Authors:  I Napoli; H Neumann
Journal:  Neuroscience       Date:  2008-07-01       Impact factor: 3.590

9.  Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.

Authors:  D Barbieri; M P Abbracchio; S Salvioli; D Monti; A Cossarizza; S Ceruti; R Brambilla; F Cattabeni; K A Jacobson; C Franceschi
Journal:  Neurochem Int       Date:  1998 May-Jun       Impact factor: 3.921

Review 10.  Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison.

Authors:  M C Dal Canto; R W Melvold; B S Kim; S D Miller
Journal:  Microsc Res Tech       Date:  1995-10-15       Impact factor: 2.769

View more
  10 in total

Review 1.  Oral Therapies for Multiple Sclerosis.

Authors:  Simon Faissner; Ralf Gold
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

Review 2.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

3.  Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation.

Authors:  Tiago Medeiros-Furquim; Sinan Ayoub; Laura J Johnson; Andrea Aprico; Eze Nwoke; Michele D Binder; Trevor J Kilpatrick
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

4.  2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.

Authors:  V Singh; C K Prajeeth; V Gudi; K Bénardais; E V Voss; M Stangel
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

5.  Cladribine modifies functional properties of microglia.

Authors:  L Ø Jørgensen; K H Hyrlov; M L Elkjaer; A B Weber; A E Pedersen; Å Fex Svenningsen; Z Illes
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

Review 6.  Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

Authors:  Emily Kamma; Wendy Lasisi; Cole Libner; Huah Shin Ng; Jason R Plemel
Journal:  J Neuroinflammation       Date:  2022-02-10       Impact factor: 8.322

Review 7.  Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.

Authors:  Simon Faissner; Ralf Gold
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 6.497

8.  The antiviral drug ganciclovir does not inhibit microglial proliferation and activation.

Authors:  Thomas Skripuletz; Laura Salinas Tejedor; Chittappen K Prajeeth; Florian Hansmann; Chintan Chhatbar; Valeria Kucman; Ning Zhang; Barbara B Raddatz; Claudia N Detje; Kurt-Wolfram Sühs; Refik Pul; Viktoria Gudi; Ulrich Kalinke; Wolfgang Baumgärtner; Martin Stangel
Journal:  Sci Rep       Date:  2015-10-08       Impact factor: 4.379

9.  In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia.

Authors:  Tanja Wostradowski; Chittappen Kandiyil Prajeeth; Viktoria Gudi; Jessica Kronenberg; Sina Witte; Marina Brieskorn; Martin Stangel
Journal:  J Neuroinflammation       Date:  2016-09-22       Impact factor: 8.322

Review 10.  The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

Authors:  Kottil Rammohan; Patricia K Coyle; Elke Sylvester; Andrew Galazka; Fernando Dangond; Megan Grosso; Thomas P Leist
Journal:  Drugs       Date:  2020-12       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.